VanEck’s, Dividend

VanEck’s Dividend Giant Earns Morningstar’s Top Mark as June Brings Payouts, Rebalancing, and a New Irish Twin

10.05.2026 - 07:41:09 | boerse-global.de

VanEck's €7.6bn TDIV ETF earns top Morningstar rating, outperforms peers with 17.9% annualized return, as new Irish-domiciled sibling TDVX begins trading ahead of June catalysts.

VanEck’s Dividend Giant Earns Morningstar’s Top Mark as June Brings Payouts, Rebalancing, and a New Irish Twin - Foto: über boerse-global.de
VanEck’s Dividend Giant Earns Morningstar’s Top Mark as June Brings Payouts, Rebalancing, and a New Irish Twin - Foto: über boerse-global.de

The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF is entering a period dense with catalysts. Morningstar just awarded the fund its highest rating, a new sister product has begun trading, and June is shaping up to be a month of structural shifts for the €7.6bn portfolio.

A Top-Tier Rating Backed by Numbers

The five-star rating, assigned on 6 May 2026, is not a rubber stamp. Morningstar also rated the fund’s investment process as “above average” and noted that its information ratio has consistently placed it among the top 10% of its peer group across all time frames.

The performance figures justify the accolade. Over five years, TDIV has delivered an annualised return of 17.9%, comfortably ahead of the category index’s 15.4% and a peer-group average of just 8.3%. The fund’s total expense ratio of 0.38% per year places it in the cheapest fifth of its category, where the median cost is 1.06%.

The share price closed on Friday at €51.80, a whisker below its 50-day moving average of €52.12. On a 12-month view, the ETF has gained roughly 22%.

Should investors sell immediately? Or is it worth buying VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF?

Pfizer Leads a Portfolio Heavy on Financials and Energy

The fund holds 115 positions. Pfizer is the largest single stock at nearly 4.7%, followed by Roche and HSBC. By sector, financials account for 31% of assets and energy for roughly 20%.

Pfizer itself provided a positive surprise just before the weekend. Adjusted earnings per share for the first quarter of 2026 came in at $0.75, roughly 4% above expectations. Revenue of $14.5bn also beat estimates. Excluding COVID-related products, the core business grew 7% year-on-year. The drugmaker confirmed its full-year guidance, with revenue forecast between $59.5bn and $62.5bn.

The Irish Sibling: TDVX Arrives

VanEck has launched a complementary fund. The VanEck Morningstar Developed Markets ex-US Dividend Leaders UCITS ETF (TDVX) began trading on Deutsche Börse and the London Stock Exchange on 23 April 2026. Its expense ratio matches TDIV at 0.38%.

The rationale for a separate vehicle is structural. TDIV is domiciled in the Netherlands, which offers tax advantages for Dutch investors but prevents the creation of an accumulating share class. Relocating the existing fund would have penalised current holders, so VanEck opted for a standalone Irish-domiciled fund instead.

The division of labour is straightforward: TDIV distributes income, TDVX reinvests it. TDIV manages €7.5bn, while TDVX is still in its early stages.

June’s Triple Whammy: Ex-Date, Payout, and Rebalance

Three events will shape June for TDIV investors. The ex-dividend date falls on 4 June, with the payout scheduled for 11 June. Over the past 12 months, the ETF has distributed €1.74 per share. The average dividend growth over the last three years has been roughly 17% annually.

At the same time, the index provider will conduct its semi-annual rebalancing. The entry criteria are strict: a stock must have paid a dividend in the past 12 months, the dividend per share must not have fallen below its five-year average, and the forward payout ratio must stay under 75%. From that pool, the index selects the 100 highest-yielding names.

VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF at a turning point? This analysis reveals what investors need to know now.

The macro backdrop adds another layer. The European Central Bank’s deposit rate stands at 2.0%, while eurozone inflation ticked up to 3.0% in April. For a fund with heavy exposure to financials and energy, that environment is worth monitoring, even if it is not immediately threatening.

Tailwinds from a Broader Rotation

The fund is catching a favourable current. Dividend-focused strategies attracted roughly $24bn in net inflows during the first quarter of 2026, the strongest quarterly showing in four years. The rotation away from US technology stocks toward capital-intensive sectors with reliable payouts plays directly into TDIV’s strengths. The MSCI All Country World ex-USA has outperformed the S&P 500 by double-digit percentage points recently, a trend that has persisted into 2026.

Technical Signals and Support Levels

The ETF’s relative strength index stands at 81, signalling heavily overbought conditions. After closing at €51.80 on Friday, the fund slipped just below its 50-day moving average. Should the decline continue, the 100-day average at €50.82 represents the next potential floor.

Between the upcoming US consumer price data for April, the rebalancing, and the dividend cycle, volatility is likely to pick up. Income-focused investors will be watching the June timeline closely as they reposition ahead of the payout.

Ad

VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock: New Analysis - 10 May

Fresh VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF analysis...

So schätzen die Börsenprofis VanEck’s Aktien ein!

<b>So schätzen die Börsenprofis  VanEck’s Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | NL0011683594 | VANECK’S | boerse | 69299634 |